Bernie Zeiher, Astellas President of Development, discusses the importance of biomarkers

Mar 7, 2017
Bernie Zeiher, Astellas President of Development, discusses the importance of biomarkers

Dr. Bernie Zeiher, Astellas President of Development, explains in a new series of videos created by the Pharmaceutical Research and Manufacturers of America (PhRMA) how innovative companies are using biomarkers to advance personalized medicines and help improve outcomes for patients.

In the videos, he explains the role of biomarkers in clinical trials, how biomarkers are used to select clinical trial participants and how biomarkers are used to assess a medicine’s effectiveness.

“Biomarkers are used in clinical studies to select patients eligible to be treated in that study,” explains Zeiher. “In the case of oncology, if you’re targeting a tumor that has a particular mutation, you’d run the test before they’re enrolled and see if they have that mutation, and if they are, they’re eligible for treatment.”

In November, Zeiher was profiled in a PhRMA video in which he discussed his highly personal entry into medicine, his reflections on more than 15 years in helping to develop innovative treatments, and his clear and unwavering optimism for the future. “The continuing motivation to bring therapies forward is there for me and hopefully for the whole industry,” Zeiher said. “I’m optimistic about the future because the promise of personalized medicines has begun to be seen.”

Bernie Zeiher, Astellas President of Development, discusses the importance of biomarkers

Astellas Patient Advocacy is a function within Corporate Affairs at Astellas that focuses on creating, building and maintaining third-party relationships. We serve as a conduit between Astellas and external stakeholders to help improve patient outcomes, improve access issues and address patients’ unmet needs head on.

Leave a Reply